# Safety and Tolerability of Yaq-001 in Patients With Cirrhosis

> **NCT03202498** · NA · TERMINATED · sponsor: **Yaqrit Ltd** · enrollment: 31 (actual)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DEVICE:** 4g Yaq-001
- **OTHER:** 4g Placebo
- **DEVICE:** 8g Yaq-001
- **OTHER:** 8g Placebo

## Key facts

- **NCT ID:** NCT03202498
- **Lead sponsor:** Yaqrit Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-28
- **Primary completion:** 2020-03-26
- **Final completion:** 2020-03-26
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** COVID-19 pandemic prevents patients from making in-hospital visits, which are mandatory to assessment of safety in this study
- **Last updated:** 2020-08-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03202498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03202498, "Safety and Tolerability of Yaq-001 in Patients With Cirrhosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03202498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*